New stroke drug shows promise in early trial
NCT ID NCT07279493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called KPCXM18 in people who have had an acute ischemic stroke within the past 12 hours. About 300 participants will receive either a low dose, a high dose, or a placebo by IV twice daily for about 12 days. The main goal is to see if the drug helps reduce disability 90 days after the stroke.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KPCXM18 injection
- What this could lead to
- If successful, this could point toward a new treatment to reduce disability after a stroke.
- What could go wrong
- This is an early Phase 2b trial with only 300 people, so results may not confirm benefit. The drug is still experimental and safety is not fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Central Hospital Of Shenyang Medical College
RECRUITINGShenyang, Liaoning, China
-
Beijing Tiantan Hosptial，Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
-
Cangzhou Central Hospital
RECRUITINGCangzhou, Hebei, China
-
Da Qing Long Nan Hospital
RECRUITINGDaqing, Heilongjiang, China
-
Daqing Oilfield General Hospital
RECRUITINGDaqing, Heilongjiang, China
-
First People's Hospital Of Tancheng
RECRUITINGLinyi, Shandong, China
-
Hengshui People's Hospital
RECRUITINGHengshui, Hebei, China
-
Jiaxing Second Hospital
RECRUITINGJiaxing, Zhejiang, China
-
Linfen Central Hospital
RECRUITINGLinfen, Shanxi, China
-
Linfen People's Hospital
RECRUITINGLinfen, Shanxi, China
-
Linyi People's Hospital
RECRUITINGLinyi, Shandong, China
-
Meihakou Central Hospital
RECRUITINGMeihekou, Jilin, China
-
Nanshi Hospital Of Nanyang
RECRUITINGNanyang, Henan, China
-
Nanyang Second General Hospital
RECRUITINGNanyang, Henan, China
-
Shenzhen Second People's Hospital
RECRUITINGShenzhen, Guangdong, China
-
Sinopharm Tongmei General Hospital
RECRUITINGDatong, Shanxi, China
-
Tengzhou Central People's Hospital
RECRUITINGTengzhou, Shandong, China
-
The First Affiliated Hospital Of Nanyang Medical College
RECRUITINGNanyang, Henan, China
-
The First People's Hospital Of Shenyang
RECRUITINGShenyang, Liaoning, China
-
The People's Hospital Of Anyang City
RECRUITINGAnyang, Henan, China
-
The People's Hospital Of Liaoning Province
RECRUITINGShenyang, Liaoning, China
-
Xuzhou Central Hospital
RECRUITINGXuzhou, Jiangsu, China
-
Yan'an University Xianyang Hospital
RECRUITINGXianyang, Shaanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?